Selective DXP Synthase Inhibitors for Drug-Resistant Bacteria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The rise of drug-resistant microorganisms has led to infections that are difficult to treat with existing antibiotics, which often suffer from toxicity and a narrow spectrum of activity, highlighting the need for effective inhibitors of bacterial 1-deoxy-D-xylulose 5-phosphate synthase to disrupt isoprenoid biosynthesis.
Innovation Solution
Development of compounds, such as benzyl acetyl phosphonate (BnAP) and other alkylacetylphosphonates, that selectively inhibit 1-deoxy-D-xylulose 5-phosphate synthase, offering a broad-spectrum approach to inhibit bacterial growth by targeting this enzyme in both bacterial and mammalian cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibiotics are used to treat infections, then bacterial growth is inhibited, but toxicity and narrow spectrum of activity limit their utility
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (aryl or heteroaryl groups at particular positions) that confer selective toxicity against bacterial DXP synthase while sparing mammalian enzymes. The localized substitution patterns create precise molecular recognition of the bacterial enzyme active site, achieving antimicrobial activity without broad mammalian toxicity.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular substituents (different aryl groups, heteroaryl groups, and their positions) to optimize the balance between bacterial inhibition and mammalian safety. By adjusting these chemical parameters, the compounds achieve enhanced selectivity for bacterial DXP synthase over mammalian ThDP-dependent enzymes.
2Reliability
If existing antibiotics are used, then some bacterial infections are treated, but narrow spectrum of activity limits their effectiveness against diverse pathogens
Solution Approach 1:
The patent achieves universality by creating a compound series that targets a conserved bacterial enzyme (DXP synthase) present across diverse pathogenic bacteria. The core molecular scaffold maintains consistent interaction with the essential catalytic mechanism of DXP synthase, while allowing variation to adapt to different bacterial species, thereby providing broad-spectrum activity against Gram-positive and Gram-negative pathogens.
3Adaptability or versatility
If selective inhibitors of DXP synthase are developed, then bacterial growth is inhibited with broad spectrum activity, but few reports describe development of selective inhibitors
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional modules: a core scaffold and variable substituent groups (aryl, heteroaryl, and their positions). This modular approach allows systematic optimization of selectivity by independently tuning each segment, making the complex structure more manageable and designable through combinatorial chemistry strategies.
Data Source
AI summary
Novel inhibitors of DXP synthase and methods of use thereof are disclosed.